| Name | Title | Contact Details |
|---|
Cellenkos is an early stage clinical biotechnology company that focuses on cord blood-derived T-regulatory cellular therapies for the treatment of autoimmune diseases and inflammatory conditions. Cellenkos is founded on the technologies arising from the laboratory investigations of Simrit Parmar, M.D. Cellenkos` lead product CK0801 delivers clinically meaningful doses of allogeneic cord blood T-regulatory cells to overcome immune dysfunction.
Hospitalists of America is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Anesthesia Service Inc is a Oklahoma City, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
St. Jude Medical is a global medical device manufacturer dedicated to transforming the treatment of some of the world’s most expensive epidemic diseases. We do this by developing cost-effective medical technologies that save and improve lives. St. Jude Medical provides safe and effective technologies that are of the highest quality—and that quality is something we take very seriously because we know patients around the world rely on our technologies. Our approximately 18,000 employees are passionate in their commitment to this priority. Headquartered in St. Paul, Minn., St. Jude Medical has four major clinical focus areas: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. The St. Jude Medical product portfolio includes implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT) devices, pacemakers, remote monitoring systems, cardiac mapping and visualization systems, catheter-based ablation devices, vascular closure devices, structural heart products, spinal cord stimulation, peripheral nerve stimulation and deep brain stimulation devices. All qualified applicants will receive consideration for employment without regard to race, color, creed, religion, sex, national origin, marital status, age, citizenship, protected veteran status, sexual orientation, gender identity and/or gender expression, status with respect to public assistance, or disability status.
At Clinipace, a global, full-service contract research organization (CRO), our approach to clinical research is personal. We deliver a level of collaboration and flexibility not possible in a traditional CRO environment. Our personalized services and solutions, local regulatory expertise and therapeutic leadership are designed to face the most difficult industry challenges across all major therapeutic areas including oncology, gastroenterology, nephrology and urology. We strive to improve the way clinical research is performed and impact the future of health care using the most advanced technology and a CHALLENGE ACCEPTED approach. In April 2021, Clinipace & dMed merged creating a differentiated mid-size CRO with the largest Asia-Pacific presence. We are proud to have such a strong group of global investors focused on improving healthcare outcomes and giving sponsors a better CRO choice. dMed`s 2019 acquisition of Target Health commenced the process of building a Next Generation global CRO for biotech and pharmaceutical companies. Our investors have invested over $230M to build the next great global CRO. dMed`s acquisition of Target Health in 2019 began dMed`s evolution from a local to global CRO. Target Health LLC is owned by dMedClinical Co. Ltd., a privately held company that is majority owned, operated, managed, and controlled by a U.S. citizen and foreign entities located in the People`s Republic of China. Dr. Lingshi Tan, is the aforementioned U.S. citizen currently residing in Shanghai, China. Dr. Tan moved to Shanghai (from New York) to become Pfizer`s VP of Worldwide Development Operations, and Chairman and General Manager of Pfizer (China) Research & Development Co. Dr. Tan founded dMed in 2016 to satisfy the local demand for a high quality, responsive, flexible CRO.